APR Corp. has announced remarkable growth in its third-quarter financial performance, with sales hitting KRW 122 billion and operating profits reaching KRW 21.9 billion. This significant year-over-year increase nearly triples the figures reported in the same period last year. The company's cumulative sales for the first three quarters of the year amounted to KRW 371.9 billion, with profits at KRW 69.8 billion, already nearing the total figures of the previous year.
The impressive results were driven by the strong performance of key products such as medicube's AGE-R device and the Booster-H beauty device, which together surpassed global unit sales of over 750,000. The GLAM.D Bio brand also contributed to the company's success. Furthermore, APR's international revenues for Q3 saw a sharp increase of over 50% compared to the previous year, reaching KRW 56.1 billion and approaching the overseas revenue total of KRW 143.7 billion reported for the entire last year.
This surge in international earnings is a clear indicator of APR's growing global presence. The company's portfolio, which includes the medicube cosmetics' Zero Pore Pad and AGE-R beauty device, has seen significant demand. The AGE-R device alone has outpaced last year's full-year volume within the first three quarters of 2023, with sales of over three-quarters of a million units worldwide. The Booster-H has also maintained strong global demand, contributing to consistent earnings across various markets. Other brands such as APRILSKIN, FORMENT, and GLAM.D Bio have significantly enhanced the overall growth figures.
In preparation for a planned listing on Korea's stock exchange (KOSPI) in the first half of 2024, APR Corp. remains committed to maintaining stability and systematic operations. This strategic move follows the company's preliminary review filing in September and is a testament to the company's focus on achieving a significant corporate milestone.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.